Central Asia Lumeichun Biotechnology Inc.
OOTC:ZYLM0.18
USD
0.00
(0.00%)
ISIN
US8888472094
CUSIP
888847209
Return %
Stock
S&P 500
1Y
-94.31
14.20
3Y
-96.95
81.12
5Y
-99.22
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Stephen W. Carnes
- Full Time Employees
- 22
- Sector
- Consumer services
- Industry
- Movies/Entertainment
- Address
- 2180 North Park Avenue Winter Park FL United States 32789
- IPO Date
- Feb 28, 2000
- Website
- toccalife.com
- Similar Companies
- Business
- Central Asia Lumeichun Biotechnology Inc. is a biotechnology and wellness enterprise that specializes in the research, cultivation, processing, and distribution of sika deer-derived nutritional products, functional beverages, traditional herbal health tonics, and agricultural bio-solutions. Founded in 2014 and headquartered in Changchun, Jilin Province, China, with administrative registration in the United States, the company operates across key business segments including Health Supplements, Medicinal Liquors and Beverages, Agricultural Biotechnology, and Cross-Border Commerce. Its core product and service portfolio comprises raw and processed pilose antler (deer velvet) extracts; Lumeichun brand medicinal liquors, health tonics, and herbal-infused spirits; dietary supplements and encapsulated formulations containing deer placenta, deer marrow powder, deer sinew, and active bioactive peptides; ready-to-drink wellness beverages and functional herbal teas infused with ginseng, cordyceps, and wolfberry; bio-organic fertilizers and customized nutritional feed additives derived from agricultural by-products; and original equipment manufacturing (OEM) and contract processing services for third-party wellness brands. Central Asia Lumeichun Biotechnology markets its products to individual consumers, health food retailers, traditional Chinese medicine pharmacies, and commercial agricultural entities across the People's Republic of China and neighboring Central Asian markets through physical specialty stores, wholesale distributors, and digital e-commerce channels. In recent operations, Central Asia Lumeichun Biotechnology Inc. has undertaken strategic restructuring and business expansion initiatives to strengthen its market presence across Central Asia and East Asia. The company established strategic trade and distribution alliances to facilitate cross-border commercialization of its functional health products and agricultural materials within Central Asian trade corridors, particularly targeting markets in Kazakhstan and Uzbekistan. To broaden its consumer demographic, the company introduced a modernized line of ready-to-drink functional health shots and low-sugar herbal wellness beverages designed for younger urban consumers, supported by collaborative research agreements with regional biotechnology institutes to improve peptide extraction efficiency and bioactive preservation. Furthermore, Central Asia Lumeichun Biotechnology upgraded its breeding facilities and processing infrastructure with enhanced digital supply chain traceability systems and expanded its direct-to-consumer sales capabilities through integrated social commerce and live-streaming retail platforms.